Compare CLFD & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLFD | ZURA |
|---|---|---|
| Founded | 1979 | 2022 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 447.2M | 521.8M |
| IPO Year | 1995 | N/A |
| Metric | CLFD | ZURA |
|---|---|---|
| Price | $28.81 | $5.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $43.50 | $13.00 |
| AVG Volume (30 Days) | 148.5K | ★ 601.3K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.76 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $85,034,000.00 | N/A |
| Revenue This Year | $11.64 | N/A |
| Revenue Next Year | $22.30 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.51 | N/A |
| 52 Week Low | $23.76 | $0.99 |
| 52 Week High | $46.76 | $7.25 |
| Indicator | CLFD | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 55.03 | 43.20 |
| Support Level | $28.61 | $5.35 |
| Resistance Level | $30.99 | $5.75 |
| Average True Range (ATR) | 1.51 | 0.34 |
| MACD | 0.29 | -0.00 |
| Stochastic Oscillator | 95.21 | 22.12 |
Clearfield Inc designs, manufactures, and distributes fiber protection, fiber management, and fiber delivery solutions to enable rapid and cost-effective fiber-fed deployment throughout the broadband service provider space prominently across North America. Its 'fiber to anywhere' platform serves the requirements of Community Broadband customers, Multiple System Operators, Large Regional Service Providers, National Carriers, and International customers (including Europe, Canada, Mexico, and Caribbean Markets). Its product offerings include Accessories, Cassettes, Cable & Drop Assemblies, Frames & Panels, Microducts, Optical Components, etc. The company derives the majority of its revenue from the United States.
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.